ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1880

Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa

Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Young3, Cristina Burroughs4 and Peter Merkel5, 1Vanderbilt University Medical Center, Franklin, TN, 2University of California Los Angeles, West Hills, CA, 3Vasculitis Foundation, Kansas City, MO, 4Health Informatics Institute, Tampa, FL, 5University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2021

Keywords: Polyarteritis nodosa, registry, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Polyarteritis nodosa (PAN) is form of medium-vessel vasculitis with an estimated annual incidence of 1 per million. The rarity of the disease makes traditional center-based approaches to research in PAN challenging. The purpose of this study was to describe an internet-based cohort of participants with a self-reported diagnosis of PAN, and, to determine how many patients met established criteria for this disease.

Methods: Participants with a self-reported diagnosis of PAN were included in a prospective, internet-based, longitudinal registry from November 2014 to May 2020. All patients completed standardized forms collecting data on disease manifestations, diagnostic testing, and treatment. Patients reporting a history of a positive test for ANCA (n=19) were excluded.

Results: 80 participants (58% female) self-reported a diagnosis of PAN without a history of ANCA. Two participants reported a history of hepatitis B viral infection. Race/ethnicity distribution: 87% Caucasian/White, 9% Asian, 8% Hispanic/Latino, 5% African American/Black, and 1% Native American. Enrollment included participants from across the world including North America (57), Europe (8), Australia (3), Asia (2), and South America (1). The mean age of onset of symptoms and diagnosis was 42.7 (SD 0.28) and 44.1 (SD 0.30) years. Only 13 participants (16%) were > 65 years old at the time of registration. Four participants were < 18 years old at the onset of symptoms.

Patients reported that the diagnosis was made based on biopsy (75%), symptoms (51%), laboratory studies (46%), or angiogram (25%) (Table 1). The most common manifestations of vasculitis included: nerve damage (87%), muscle pain (86%), skin involvement (76%), weight loss (60%), and testicular pain (53% of males) (Table 1). Blood clots were reported in 18%. 6 participants reported only skin involvement. The majority (83%) of patients reported that a rheumatologist was their treating physician (Table 2). The most common drug exposures included glucocorticoids (86%), cyclophosphamide (49%), and azathioprine (45%) (Table 2). 95% of participants met the 1990 American College of Rheumatology Classification Criteria for PAN. 95% of participants met the 2012 Chapel Hill Consensus Conference Definition of PAN.

Conclusion: In an internet platform based on self-reported patient information, the majority of patients met well-established criteria for PAN and reported disease manifestations in similar frequencies to published data from physician-reported cohorts. These results support the use of online patient cohorts to conduct research in PAN.

Table 1: Means of diagnostic confirmation and manifestations of polyarteritis nodosa.

Table 2: Treating physicians and reported medications at enrollment.


Disclosures: J. Springer, None; T. Kermani, None; D. Shaw, None; K. Young, None; C. Burroughs, None; P. Merkel, AbbVie, 2, 5, AstraZeneca, 2, 5, Boeringher-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, 5, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 2, EMDSerono, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Magenta, 2, Neutrolis, 2, Novartis, 2, Pfizer, 2, Sanofi, 5, Star Therapeutics, 2, Takeda, 2, Talaris, 2, UpToDate, 9.

To cite this abstract in AMA style:

Springer J, Kermani T, Shaw D, Young K, Burroughs C, Merkel P. Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/description-of-an-internet-based-cohort-with-a-self-reported-diagnosis-of-polyarteritis-nodosa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/description-of-an-internet-based-cohort-with-a-self-reported-diagnosis-of-polyarteritis-nodosa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology